Compare Heron Therapeutics Inc (HRTX) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Xpeng Inc - ADR — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Xpeng Inc - ADR trades at $13.38 (market cap $12.96B). The key difference: Xpeng Inc - ADR is far larger — about 141.7× Heron Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| HRTX | XPEV | |
|---|---|---|
Market Cap | $91.46M | $12.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.96 | $28.07 |
52-Week Low | $0.39 | $12.09 |
Enterprise Value | $189.36M | $15.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.48, up 2.06% today, with a bullish technical signal but mixed earnings performance. The company reported Q1 2026 revenue of $151M but missed EPS estimates with a $0.04 loss. Despite negative net income margins, analyst consensus remains overwhelmingly bullish with 18 buy ratings. Recent patent litigation developments and seasonal pressures have impacted quarterly results.
Outlook remains challenged by ongoing losses and competitive pressures, though strong analyst support suggests potential upside if execution improves. Key risks include patent litigation outcomes, cash flow sustainability, and ability to achieve profitability. The stock's low price presents speculative opportunity but requires careful risk management.
XPeng (XPEV) trades at $13.33, down 1.52% today, with a bearish technical signal and neutral oscillators. Revenue grew to $76.72B in 2025, but net income remained negative at -$1.14B, with improving margins. Recent news highlights global expansion, including the L03 SUV launch in Munich and Robotaxi testing, while Q2 2026 deliveries of 103,295 vehicles beat expectations, signaling demand recovery.
The stock offers upside to the $17.00 analyst target but faces risks from intense EV competition and persistent losses. Investor sentiment is mixed, with 64.7% of analysts rating it Buy, yet technical trends and cash flow volatility warrant caution. Key catalysts include new model launches and international growth, but profitability remains a critical hurdle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
